can tirzepatide cause heart issues Effects of on circulatory overload and end-organ damage in failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial Tirzepatide and Cardiovascular Outcomes: A

There is solid support for gastroparesis, stomach paralysis, gastrointestinal obstruction, and ileus (bowel obstruction)

In this article we have highlighted important clinical trial data that support the pharmacotherapy of obesity

Overall glucose concentrations are better controlled throughout the day and after meals, and most people lose some weight

Peptide is cheaper than treating a soft-tissue infection

How we hold ourselves accountable for safe, credible care at every step, from your first intake to your latest check-in

In 2022, updated Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines recommended SGLT2i as first-line therapy for patients with estimated glomerular filtration rate (eGFR) 20 mL/min/1.73 m 2 (previously 30 mL/min/1.73 m 2 ) and GLP-1 RA as an additional therapy option for patients with insufficient glycemic control as part of a comprehensive risk-reduction approach for people with type 2 diabetes and CKD [5, 6, 14]